To print: Select File and then Print from your browser's menu

Title: FDA Approves Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol for Perennial and Seasonal Allergic Rhinitis

"FDA Approves Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol for Perennial and Seasonal Allergic Rhinitis"

BRIDGEWATER, NJ -- April 15, 2004 -- Aventis today announced that the U.S. Food and Drug Administration (FDA) has approved Nasacort HFA (triamcinolone acetonide) Nasal Aerosol for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and children age 6 and older. Nasacort HFA Nasal Aerosol is the first intranasal corticosteroid dry-aerosol formulation approved in the U.S. that contains hydrofluoroalkane (HFA), rather than chlorofluorocarbons (CFCs). Nasacort HFA Nasal Aerosol will provide physicians and patients with a new option for those seeking a dry-aerosol formulation for the management of nasal allergy symptoms. It replaces Nasacort® Nasal Inhaler, which was taken off the market in July 2003 to comply with Environmental Protection Agency (EPA) and FDA requirements intended to protect the ozone layer and that required the removal of nasal inhalers containing CFCs from the U.S. market. In placebo controlled clinical trials, the most commonly reported side effects were sneezing, headache, nasal irritation and rhinitis. SOURCE: Aventis

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.